Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 16/20 | 0.50 |
| ▸ | PDCD1 | Q15116 | 4/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | RARB | P10826 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13117550 | 0.93 | CD274 (0.51) | CD274PDCD1S1PR1S1PR3 | |
| SCHEMBL13117545 | 0.88 | CD274 (0.47) | CD274PDCD1S1PR1S1PR3 | |
| SCHEMBL13117512 | 0.86 | VDR (0.44) | CD274PDCD1S1PR1S1PR3RARB | |
| SCHEMBL13117549 | 0.84 | CD274 (0.57) | CD274PDCD1S1PR1S1PR3 | |
| SCHEMBL13117511 | 0.82 | CD274 (0.38) | CD274PDCD1S1PR1S1PR3RARB | |
| SCHEMBL13139660 | 0.81 | CD274 (0.54) | CD274PDCD1S1PR1S1PR3 | |
| SCHEMBL13140089 | 0.80 | RARB (0.40) | CD274PDCD1RARB | |
| SCHEMBL13117745 | 0.79 | CD274 (0.42) | CD274PDCD1 | |
| SCHEMBL13117566 | 0.79 | CD274 (0.51) | CD274PDCD1S1PR1S1PR3 | |
| SCHEMBL2910351 | 0.77 | CD274 (0.47) | CD274PDCD1S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267775-A1 | OXADIAZOLIDINEDIONE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267775-A1 | OXADIAZOLIDINEDIONE COMPOUND | GPR119, GLP1R, GPR4 | CD274 1333/4885PDCD1 1246/4885S1PR1 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.